This randomized controlled trial (PMID: 36912538) followed 1643 men aged 50-69 years with localized prostate cancer over 15 years, comparing outcomes of active monitoring, surgery, and radiotherapy. Prostate cancer-specific mortality was low across all groups (3.1%) with no significant difference between treatments, but active monitoring had higher rates of progression
